Earlier this month 33 members of Congress sent a letter to President Obama asking him to use executive authority to tackle the crisis of high drug prices in the U.S. The gist of the letter is that Congress is paralyzed (surprise surprise) to act. So, while we wait, and wait, and wait for Congress — the urgency of high drug prices calls for executive action.
One of the steps recommended is to expressly permit Americans to import lower cost medications for personal use. Well, Americans already do that and while its technically illegal, people aren’t prosecuted for doing so, and thus it’s generally permitted. But if it was expressly permitted it would remove the stigma of illegality, embolden many more consumers to import lower cost medication, deflate and defang the scare tactics of the pharmaceutical industry about importation and online pharmacies, and would instill more price competition into the U.S. market to bring down prices at local pharmacies.
A few questions. Don’t we need to pass a new law to “legalize” importation? Why do I choose to bold the phrase expressly permit? Would it be legal or expressly permitted? Maybe both? (more…)
Tagged with: bayh-dole, Congressional progressive caucus, march in rights, pay for delay
Brand name drug manufacturers made an estimated $98 billion in sales over the past eight years by paying generic manufacturers to postpone selling low-cost generic drugs, according to a new report released by the U.S. Public Interest Research Group (PIRG). These “pay for delay” deals were recently the focus of a U.S. Supreme Court decision in which the Court ruled that companies engaging in them could be prosecuted under anti-trust laws.
PIRG’s analysis found that pay for delay agreements postponed market entry of generic drugs for an average of five years. It also found that the prices for delayed generics were on average ten times less than their brand-name counterparts.
Americans are too often victims to these higher brand name drug prices, especially those who pay for their drugs out of pocket. For example, the antidepressant Effexor XR costs $194 for a 30 day supply. Venlafaxine, the generic equivalent, costs only $17. Annually, that’s $2,124 cheaper. The venlafaxine pay for delay deal could have cost a consumer $9,983 over its 4.7 year duration.
The extra costs add up quickly. The FTC found in 2010 that these deals add $3.5 billion annually in increased healthcare costs for consumers and taxpayers, not to mention the negative health outcomes of some people skipping medication because of high costs.
We hope the Supreme Court decision will encourage the FTC to challenge and put an end to anticompetitive tactics by drug companies. In the meantime, as Americans wait for domestic action, they can find much lower cost brand medication in Canada and other international pharmacies by comparing prices on PharmacyChecker.com.
Tagged with: FTC, pay for delay, PIRG, Supreme Court
This week, the U.S. Supreme Court ruled in favor of consumers over drug companies by ruling that pay-to-delay tactics by pharmaceutical companies could violate antitrust laws. This could mean speedier access to low-cost generic drugs, greater prescription adherence among cash-strapped Americans, and lower healthcare payments for taxpayers.
In this landmark case, Federal Trade Commission vs. Actavis, the Court decided 5-3 that generic drug company Actavis may have violated federal anti-trust laws in accepting payment from a brand name drug company, Solvay Pharmaceuticals, to delay manufacturing a generic version of AndroGel. An important caveat of the decision is that patent settlements between drug companies are not unlawful by definition but that the law is flexible enough on a case by case basis to conclude that pay-to-delay is anti-competitive, and under some circumstances illegal.
The FTC has estimated that Americans spend an extra $3.5 billion each year because of pay-to-delay practices. If drug companies are deterred from attempting pay-to-delay agreements then more generics will be found on U.S. pharmacy shelves faster. FTC Chairwoman Edith Ramirez summed up the decision: “The Supreme Court’s decision is a significant victory for American consumers, American taxpayers and free markets.”
Tagged with: pay for delay, Solvay, Supreme Court